论文部分内容阅读
目的：检测乳腺良恶性病变癌ｃ－ｍｙｃ表达及与ＤＮＡ倍体的关系。方法：利用免疫组化（ＬＳＡＢ）法和图像分析技术对乳腺癌８２例和乳腺良性病变２２例进行ｃ－ｍｙｃ蛋白免疫组化检测。结果：ｃ－ｍｙｃ蛋白免疫组化染色的着色面积与着色深度高度相关（Ｐ＜０．０１），着色深度和着色面积又与平均灰度、平均光密度及平均积分光密度高度相关。ｃ－ｍｙｃ癌基因蛋白在乳腺良恶性病变表达率差别无统计学意义（Ｐ＜０．０５）。但良性病变ｃ－ｍｙｃ染色多呈轻度阳性，少数呈中到强度阳性，而且着色部位多以胞核胞质均着染色。恶性肿瘤ｃ－ｍｙｃ免疫组化染色多呈中到强度阳性，少数呈弱阴性，且以胞质着色为主，二者之间差别有显著意义（Ｐ＜０．０５）。结论：乳腺良恶性病变都可有ｃ－ｍｙｃ激活，ｃ－ｍｙｃ与细胞增殖有关，并非恶性肿瘤所特有。但结合着色程度及着色部位对良恶性病变的鉴别仍然有意义。
Objective: To detect the expression of c-myc and its relationship with DNA ploidy in benign and malignant breast lesions. Methods: Immunohistochemistry (LSAB) and image analysis were used to detect the expression of c-myc protein in 82 cases of breast cancer and 22 cases of benign breast lesions. Results: The staining area of c-myc protein was highly correlated with the color depth (P <0.01). The color depth and the color area were highly correlated with the average gray level, the average optical density and the average integrated optical density. There was no significant difference in the expression rates of c-myc oncogene protein between benign and malignant breast lesions (P <0.05). However, benign lesion c-myc staining were mostly mild positive, a few were moderate to strong positive staining and cytoplasm staining were mostly cytoplasm. Immunohistochemical staining of c-myc in malignant tumors was mostly moderate to moderate in intensity with a few in weakly negative ones. Cytoplasmic staining was the main method. The difference between them was significant (P <0.05). Conclusion: Both benign and malignant breast lesions may have c-myc activation. C-myc is associated with cell proliferation and is not unique to malignant tumors. However, the combination of the degree of coloring and staining of benign and malignant lesions still makes sense.